Images List Premium Download Classic

Immunogenic

Immunogenic-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Method for enhancing immunogenicity of epitope peptide of hpv antigen, virus-like particle, and method for ...
Tianjin Cansino Biotechnology Inc.
June 15, 2017 - N°20170166612

A method for enhancing immunogenicity of an epitope peptide of an hpv antigen, the method including: assembling a gene of an hpv antigen into a gene of hbc, exogenously expressing a resulting assembled gene to acquire a fusion protein, allowing the fusion protein to automatically assemble to form a virus-like particle including the hpv antigen on a surface of the ...
Methods for enhancing the immunostimulation potency of aluminum salt-absorbed vaccines
The Government Of The United States Of America As Reprisented By Secretary Of The Army
June 15, 2017 - N°20170165358

Provided herein are (1) a method of mixing an aluminum salt-adsorbed immunogen with a monophosphoryl lipid a (mpla)-containing liposome (l(mpla)), and (2) the resulting immunogenic composition. The resulting immunogenic composition has an enhanced immunostimulation potency compared with either a composition comprising the uncapsulated immunogen mixed with the l(mpla) or the aluminum salt-adsorbed immunogen alone.
Helicobacter therapeutic
Murdoch Childrens Research Institute
June 15, 2017 - N°20170165347

The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express htra. The present invention further relates to immunogenic compositions comprising an htra polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.
Immunogenic Patent Pack
Download 328+ patent application PDFs
Immunogenic Patent Applications
Download 328+ Immunogenic-related PDFs
For professional research & prior art discovery
inventor
  • 328+ full patent PDF documents of Immunogenic-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
The Trustees Of The University Of Pennsylvania
June 08, 2017 - N°20170159027

Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of raav particles. Aav-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.
A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in ...
Centre National De La Recherche Scientifique
June 08, 2017 - N°20170158740

The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (mv) particles. The present invention ...
Methods and compositions for liposomal formulation of antigens and uses thereof
The Regents Of The University Of California
June 08, 2017 - N°20170157266

The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“dmpc”); either dimyristoylphosphatidylglycerol (“dmpg”) or dimyristoyltrimethylammonium propane (“dmtap”) or both dmpc and dmtap; and at least one ...
Immunogenic Patent Pack
Download 328+ patent application PDFs
Immunogenic Patent Applications
Download 328+ Immunogenic-related PDFs
For professional research & prior art discovery
inventor
  • 328+ full patent PDF documents of Immunogenic-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods of enhancing immunogenicity of polysaccharide protein conjugates
Kanvax Biopharmaceuticals Ltd
June 08, 2017 - N°20170157241

The present invention provides compositions and methods for enhancing immunogenicity of polysaccharide antigens. Immunogenic compositions and vaccines comprising polysaccharide-protein conjugates comprising a chimeric carrier protein having a universal epitope are provided. Methods of preparing the compositions, and methods for treating or preventing bacterial infections are further provided. The compositions and methods are useful for enhancing immune response in young children, ...
Immunogenic compositions
Sanofi Pasteur Limited
June 08, 2017 - N°20170157233

This disclosure relates to immunogenic compositions comprising an isolated immunogenic s. Pneumoniae pcpa polypeptide, at least one additional antigen (such as for example, an isolated immunogenic s. Pneumoniae polypeptide selected from the group consisting of the polyhistidine triad family of proteins (e. G., phtd), and at least one isolated detoxified pneumolysin (e. G., plyd1) and methods of using these compositions ...
Immunogenic polypeptide composed of hla-b7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof
Vaxon Biotech
June 08, 2017 - N°20170157228

The invention pertains to an optimized chimeric polypeptide for use in hla-337 cancer patients, which comprises four optimized peptides derived from cryptic tumor epitopes (cea, tert, mage and her-2/neu) to enhance their immunogenicity.
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule ...
Jomoco, Corp.
June 08, 2017 - N°20170157215

Methods and compositions for preventing an immune response to an immunogenic therapeutic agent [i. E. Anti-drug antibody (ada), a. K. A. Anti-therapeutic antibody (ata)] are disclosed. One of the disclosed methods comprises administering an effective amount of an immunosuppressant such as an il-2 signaling pathway inhibitor, including an antagonist, super agonist or partial agonist to the cytokine il-2, to the ...
Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection
City Of Hope
June 01, 2017 - N°20170152480

A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (egfrt) that lacks the membrane distal egf-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-egfr antibody is provided. Cells may be genetically modified to ...
Recombinant swine influenza virus and uses thereof
University Of Saskatchewan
June 01, 2017 - N°20170151323

Recombinant, chimeric porcine influenza viruses are disclosed that include hemagglutinin segments from more than one influenza virus subtype. Also described are methods of producing the recombinant influenza viruses, immunogenic compositions comprising the recombinant influenza viruses, methods of stimulating an immune response against influenza virus, and methods of treating and preventing influenza virus infection.
Chimeric pestiviruses
Zoetis Services Llc
June 01, 2017 - N°20170151321

The present invention relates to chimeric pestiviruses having utility as immunogenic compositions and vaccines. Also described herein are methods and kits for treating or preventing the spread of bovine viral diarrhea virus infection, as well as methods and kits for differentiating between vaccinated and wild-type infected animals.
Immunogenic Patent Pack
Download 328+ patent application PDFs
Immunogenic Patent Applications
Download 328+ Immunogenic-related PDFs
For professional research & prior art discovery
inventor
  • 328+ full patent PDF documents of Immunogenic-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity ...
Zoetis Services Llc
May 25, 2017 - N°20170146526

Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional apcs (papcs) result in the generation of autologous apcs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e. G., a cytotoxic t lymphocyte (ctl) response to a particular ...
Immunogenic combinations
Zoetis Services Llc
May 25, 2017 - N°20170143820

Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit ...
Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
Zoetis Services Llc
May 25, 2017 - N°20170143810

Disclosed herein are an immunogenic glycopeptide for inducing immune response to treat cancer. Other aspects of the present disclosure are pharmaceutical composition comprising the immunogenic glycopeptide; and method for preventing and/or treating a cancer.
Compounds and methods for use in detecting gabapentin
Ark Diagnostics, Inc.
May 18, 2017 - N°20170138970

Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.
Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
Merial, Inc.
May 18, 2017 - N°20170137843

The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an ox40l polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the ox40l polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. ...
Anti-tumor necrosis factor-alpha agents and uses thereof
Technophage, InvestigaÇÃo E Desenvolvimento Em Biotecnologia, Sa
May 18, 2017 - N°20170137510

The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against tumor necrosis factor-alpha, in particular, two light chain variable domains in dimeric form, where the dimer has high solubility. It also relates to methods of using anti-tumor necrosis factor-alpha polypeptides in treating inflammatory disorders, including rheumatoid arthritis. Compositions and methods for ...
Fibronectin binding domains with reduced immunogenicity
Bristol-myers Squibb Company
May 18, 2017 - N°20170137494

Fibronectin type iii (10fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10fn3 binding domains in which hla anchor ...
Compositions and methods for rendering tumor cells susceptible to cd8+ t cell-mediated killing
Bristol-myers Squibb Company
May 18, 2017 - N°20170137493

Wherein, t is a single chain variable portion fragment of a monoclonal antibody (scfv) directed to a target protein, polypeptide, or fragment thereof, which is highly expressed on cancer cells; e is two or more foreign immunogenic cd8+ t cell antigenic epitopes; c is a peptide or polypeptide fragment thereof, capable of being cleaved by a specific protease; and fc ...
Loading